Please use this identifier to cite or link to this item:

TitleTargetability of hyaluronic acid nanogel to cancer cells: In vitro and in vivo studies
Author(s)Pedrosa, Sílvia S.
Pereira, Paula
Correia, A.
Gama, F. M.
KeywordsHyaluronic acid
Cancer nanotechnology
Non-invasive imaging
Non-small cancer lung cells
Issue date15-Jun-2017
JournalEuropean Journal of Pharmaceutical Sciences
CitationPedrosa, Sílvia S.; Pereira, Paula; Correia, A.; Gama, F. M., Targetability of hyaluronic acid nanogel to cancer cells: In vitro and in vivo studies. European Journal of Pharmaceutical Sciences, 104, 102-113, 2017
Abstract(s)We have, in previous work developed, characterized and evaluated the biocompatibility of an engineered hyaluronic acid nanogel. Here we assess the targetability of a hyaluronic acid nanogel towards CD44 overexpressing cells, in vitro and in vivo. Results obtained by flow cytometry and confocal fluorescence microscopy shows that nanogel is greatly internalized by non-small cancer lung cells (A549 cells), that overexpress CD44 receptors. The biodistribution and tumor targetability of the nanogel labelled with a near-infrared (NIR) probe were performed, in mice, through a non-invasive imaging system. Results revealed nanogel high targetability towards an induced subcutaneous A549 tumor. Nanogels pharmacokinetics was evaluated also in healthy animals, and Alexa Fluor 680 labelled nanogel exhibited higher accumulation in liver, kidneys and skin. Also, a comparative biodistribution study was performed, using two NIR imaging probes, Cy5.5 and Alexa Fluor 680.
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_46748_1.pdf2,18 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID